The wider loss is almost entirely non-cash: a $3.85 million warrant revaluation hit that grew because the stock went up. What matters is the $33.2 million cash balance as of November 12, enough to fund operations into Q1 2028 and carry the Phase III MAVERIC pericarditis trial to topline results in mid-2027.
Cardiol Therapeutics Inc - Class A
CRDL at a Glance
- Market cap
- $110.1M
- EPS (TTM)
- $-0.24
- 52-week range
- $1 – $2
- Street target
- $8.40
Headquartered in Oakville, ON Fiscal year ends December NASDAQ: CRDL cardiolrx.com
About Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage, pre-revenue life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its shares trade on the TSX and the Nasdaq Capital Market under the symbol CRDL.
Its lead small-molecule candidate, CardiolRx, modulates activation of the NLRP3 inflammasome pathway, which plays a role in inflammation and fibrosis in pericarditis, myocarditis and heart failure. CardiolRx is being evaluated in the pivotal Phase III MAVERIC trial in recurrent pericarditis. That trial is a randomized, double-blind, placebo-controlled US study now expanding to up to 150 patients, with topline results expected in mid-2027. CardiolRx holds FDA Orphan Drug Designation for pericarditis.
CardiolRx was also studied in the completed Phase II ARCHER trial in acute myocarditis, where next steps are under review. The company is separately developing CRD-38, a subcutaneously administered cannabidiol formulation for heart failure and other inflammatory cardiac conditions, which is in IND-enabling studies.
Cardiol has no operating revenues and funds operations through equity financings, warrant exercises and a US$75 million at-the-market program. It relies on contract research organizations for clinical work and may partner with pharmaceutical companies for late-stage development and commercialization. Updated
Frequently Asked Questions
What does Cardiol Therapeutics do?
Cardiol Therapeutics Inc. is a late-stage, pre-revenue life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its shares trade on the TSX and the Nasdaq Capital Market under the symbol CRDL.
What is the CRDL stock price target?
The Wall Street consensus 12-month price target for CRDL is $8.40.